GLAXO Pharmaceuticals: Major
Health Technology
316.60 +1.20%
Mkt Cap
99.6B
P/E (TTM)
9.57
EPS (TTM)
32.69
ROE (TTM)
32.68%
Div Yield
6.00%
GlaxoSmithKline Pakistan Limited (GLAXO) Financial Statements, Ratios & Dividends
About
GlaxoSmithKline Pakistan Ltd. is a healthcare company, which engages in the manufacturing and marketing research-based vaccines, medicines, and consumer healthcare products. It operates through the Pharmaceutical segment. The company was founded in 1947 and is headquartered in Karachi, Pakistan.
Financial Highlights
| FY2025 | FY2024 | ||
|---|---|---|---|
| Revenue | 65.90B | 61.19B | |
| Gross Profit | 22.94B | 14.46B | |
| Net Income | 10.03B | 6.54B | |
| EPS | 31.48 | 20.52 | |
| ROE | 32.37% | 26.17% | |
| ROA | 20.61% | 15.48% | |
| Gross Margin | 34.81% | 23.63% | |
| Net Margin | 15.21% | 10.68% | |
| Current Ratio | 2.32 | 2.06 | |
| DPS | 17.00 | 10.00 | |
| Free Cash Flow | 6.60B | 2.82B |
| FY2025 | FY2024 | ||
|---|---|---|---|
| Total Revenue | 65.90B | 61.19B | |
| Cost of Goods Sold | -42.96B | -46.73B | |
| Gross Profit | 22.94B | 14.46B | |
| SG&A Expenses | -7.06B | -6.25B | |
| Research & Development | -181.45M | -113.93M | |
| Depreciation | -1.37B | -1.14B | |
| Other Operating Expense | -275.51M | -139.17M | |
| Total Operating Expense | -50.30B | -53.12B | |
| Operating Income (EBIT) | 15.60B | 8.07B | |
| Interest Income | 518.14M | 538.91M | |
| Interest Expense | -116.39M | -91.66M | |
| Equity in Earnings | 0 | 0 | |
| Other Non-Operating Income | 745.22M | 1.98B | |
| Total Non-Operating Income | 1.08B | 2.41B | |
| Pre-Tax Income | 16.68B | 10.48B | |
| Income Tax | -6.66B | -3.94B | |
| Minority Interest | 0 | 0 | |
| Net Income | 10.03B | 6.54B | |
| EBITDA | 16.97B | 9.20B | |
| EPS (Basic) | 31.48 | 20.52 | |
| EPS (Diluted) | 31.48 | 20.52 | |
| Gross Margin | 34.81% | 23.63% | |
| Operating Margin | 23.67% | 13.19% | |
| EBITDA Margin | 25.76% | 15.04% | |
| Pre-Tax Margin | 25.32% | 17.12% | |
| Net Margin | 15.21% | 10.68% |
| FY2025 | FY2024 | ||
|---|---|---|---|
| Profitability | |||
| Return on Equity (ROE) | 32.37% | 26.17% | |
| Return on Assets (ROA) | 20.61% | 15.48% | |
| Return on Invested Capital | 32.12% | 26.03% | |
| Gross Margin | 34.81% | 23.63% | |
| Operating Margin | 23.67% | 13.19% | |
| EBITDA Margin | 25.76% | 15.04% | |
| Net Margin | 15.21% | 10.68% | |
| Pre-Tax Margin | 25.32% | 17.12% | |
| Liquidity | |||
| Current Ratio | 2.32 | 2.06 | |
| Quick Ratio | 1.43 | 1.26 | |
| Leverage | |||
| Debt / Equity | 0.01 | 0.01 | |
| Debt / Assets | 0.01 | 0.00 | |
| LT Debt / Equity | 0.01 | 0.01 | |
| LT Debt / Assets | 0.01 | 0.00 | |
| Net Debt | -9.28B | -7.56B | |
| Total Debt | 368.11M | 173.65M | |
| Efficiency | |||
| Asset Turnover | 1.35 | 1.45 | |
| Inventory Turnover | 3.40 | 3.90 | |
| Per Share | |||
| Book Value Per Share | 105.74 | 88.79 | |
| Tangible Book Per Share | 102.74 | 85.79 | |
| Cash Per Share | 30.28 | 24.30 | |
| Total Debt Per Share | 1.16 | 0.55 | |
| Working Capital Per Share | 62.87 | 49.51 | |
| Shares & Market | |||
| Total Shares Outstanding | 318,467,278 | 318,467,278 | |
| Market Cap | 124.13B | 126.40B | |
| Enterprise Value | 114.86B | 118.84B | |
| Employees | 1,606 | 1,690 | |
| Shareholders | 12,751 | 12,751 | |
| FY2025 | FY2024 | ||
|---|---|---|---|
| Dividends Per Share | 17.00 | 10.00 | |
| Dividend Yield | 4.36% | 2.52% | |
| Payout Ratio | 54.00% | 48.72% | |
| Total Dividends Paid | -4.74B | -1.75M |
| FY2025 | FY2024 | ||
|---|---|---|---|
| P/E Ratio | 12.38 | 19.34 | |
| P/B Ratio | 3.69 | 4.47 | |
| P/S Ratio | 1.88 | 2.07 | |
| P/CF Ratio | 13.52 | 22.59 | |
| EV/EBITDA | 6.77 | 12.91 | |
| Market Cap | 124.13B | 126.40B | |
| Enterprise Value | 114.86B | 118.84B |
| TTM | ||
|---|---|---|
| Income | ||
| Revenue | 67.12B | |
| Gross Profit | 25.60B | |
| Operating Income | 17.88B | |
| Net Income | 10.41B | |
| EBIT | 17.88B | |
| Free Cash Flow | 7.07B | |
| EPS (Basic) | 32.69 | |
| Margins | ||
| Gross Margin | 38.15% | |
| Operating Margin | 26.65% | |
| Net Margin | 15.51% | |
| Returns | ||
| Return on Equity (ROE) | 32.68% | |
| ROIC | 0.32% | |
| Coverage & Debt | ||
| Dividend Coverage | 2.10 | |
| Debt / Revenue | 0.01 | |
| Valuation & Scores | ||
| P/E (TTM) | 9.57 | |
| Sloan Ratio | 5.83 | |
| Zmijewski Score | -3.26 | |
Computed Metrics (Latest Period)
| FY2025 | ||
|---|---|---|
| Extended Returns | ||
| Return on Common Equity | 32.37% | |
| Return on Tangible Equity | 33.40% | |
| Return on Tangible Assets | 21.02% | |
| Return on Total Capital | 49.93% | |
| ROCE | 46.41% | |
| Growth | ||
| EPS Diluted Growth | 0.53% | |
| Sustainable Growth Rate | 14.89% | |
| Quality & Risk Scores | ||
| Piotroski F-Score | 6 | |
| Zmijewski Score | -3.23 | |
| Sloan Ratio | 6.11 | |
| Valuation (Computed) | ||
| Graham Number | 273.67 | |
| Tobin's Q Ratio | 2.41 | |
| Leverage & Coverage | ||
| Interest Coverage | 134.0x | |
| Total Debt / Capital | 0.01% | |
| Assets / Equity (Leverage) | 1.53 | |
| Net Debt / EBITDA | -0.55 | |
| Effective Interest Rate | 42.97% | |
| Debt / Revenue | 0.01 | |
| Efficiency (Computed) | ||
| Fixed Asset Turnover | 4.76 | |
| Receivables Turnover | 5.78 | |
| Dividends (Computed) | ||
| Payout Ratio | 0.54% | |
| Dividend Coverage | 2.59 | |
| Share Buyback Ratio | 0.00 | |
| Per Employee | ||
| Revenue / Employee | 41.03M | |
| Net Income / Employee | 6.24M | |
| Oper. Income / Employee | 9.71M | |
| Total Assets / Employee | 32.11M | |
| Balance Sheet (Computed) | ||
| Tangible Assets | 50.62B | |
| Invested Capital | 34.01B | |
| Working Capital | 20.02B | |
| Book Value Per Share | 105.74 | |
| Earnings Schedule | ||
| Next Earnings Date | 3 Mar 2027 | |
| Next Fiscal Period | 2026 | |